Idorsia (XSWX:IDIA) Risk Assessment

View and export this data going back to 2017. Start your Free Trial

What is Idorsia Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Idorsia is: High Risk: High uncertainty.

Competitive Comparison of Idorsia's Risk Assessment

For the Biotechnology subindustry, Idorsia's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Idorsia's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Idorsia's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Idorsia's Risk Assessment falls into.

Idorsia (XSWX:IDIA) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Idorsia Risk Assessment Related Terms

Thank you for viewing the detailed overview of Idorsia's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Idorsia (XSWX:IDIA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Idorsia Ltd (XSWX:IDIA) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

IDRSF:USA IDIAz:UK 0RQE:UK

Address

Hegenheimermattweg 91, Allschwil, CHE, 4123

Website

https://www.idorsia.com

Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. It is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide innovative therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. Idorsia's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.

Idorsia (XSWX:IDIA) Headlines

No Headlines